Form 4: Fate Therapeutics Officer Sells Shares for Tax Obligations

Cindy Tahl, Chief Legal and Compliance Officer at Fate Therapeutics, sold 10,589 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Cindy Tahl, Chief Legal and Compliance Officer of Fate Therapeutics Inc. (FATE), sold 10,589 shares of common stock on January 9, 2026.
• The shares were sold at a weighted average price of $1.0648 per share, with prices ranging from $1.05 to $1.09.
• The sale was a "sell-to-cover" transaction to satisfy tax withholding obligations arising from the vesting of 17,500 shares of Restricted Stock Units (RSUs) granted on January 15, 2025, and 8,326 shares of RSUs granted on January 25, 2022.
• This transaction was automatically executed pursuant to an irrevocable election by the Reporting Person and was not made at the discretion of the Reporting Person.
• Following the transaction, Cindy Tahl beneficially owns 387,081 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine "sell-to-cover" transaction by an officer to satisfy tax obligations upon RSU vesting. This is a standard event related to executive compensation and does not indicate a discretionary negative view on the stock, though the sale price is relatively low.

Positives

• The vesting of 25,826 Restricted Stock Units (RSUs) indicates ongoing compensation and retention of a key officer.
• The transaction was a non-discretionary "sell-to-cover" to meet tax obligations, not a voluntary sale of shares, suggesting no lack of confidence in the company by the officer.

Negatives

• The sale of 10,589 shares reduces the direct beneficial ownership of the Chief Legal and Compliance Officer.
• The weighted average sale price of $1.0648 per share is relatively low, potentially reflecting the company's current stock valuation.

Risks

• NA

Future Outlook

NA

Management Comments

• Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 17,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 15, 2025 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022.
• These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.

Industry Context

NA

Comparison to Industry Standards

• NA

Related Party Transactions

• Sale of 10,589 shares of common stock by Cindy Tahl, Chief Legal and Compliance Officer, to cover tax withholding obligations related to RSU vesting, which is a standard related party dealing for executive compensation.

Stakeholder Impact

• Shareholders: Minor reduction in an officer's direct beneficial ownership, but the transaction is routine and reflects executive compensation rather than a discretionary sale.
• Management: Cindy Tahl's beneficial ownership remains substantial (387,081 shares), indicating continued alignment with shareholder interests despite the tax-related sale.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary "sell-to-cover" transaction by an executive to satisfy tax obligations upon RSU vesting. It does not signal a change in management's confidence or a strategic shift. While the sale reduces the officer's direct holdings, the underlying RSU vesting represents ongoing compensation. The transaction itself provides no new fundamental information to warrant a change in investment thesis, thus a "hold" recommendation is appropriate.

Keywords

Fate Therapeutics, FATE, insider transaction, Form 4, stock sale, RSU vesting, tax withholding, executive compensation, Cindy Tahl